ALN-APP for Cerebral Amyloid Angiopathy
(cAPPricorn-1 Trial)
Trial Summary
What is the purpose of this trial?
The purpose of the study is to evaluate the effect of ALN-APP on measures of CAA disease progression and to characterize the safety, tolerability, and pharmacodynamics (PD) of ALN-APP in adult patients with sporadic CAA (sCAA) and Dutch-type CAA (D-CAA). The study will be conducted over 2 periods: a 24-month double-blind treatment period and an optional 18-month open-label extension (OLE) period. The estimated duration of study participation, inclusive of screening, treatment, and additional safety follow-up, is up to 50 months.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. However, if you have recently received an investigational agent or have been treated with an amyloid-targeting antibody, you may not be eligible to participate.
How is the drug ALN-APP different from other treatments for cerebral amyloid angiopathy?
Research Team
Medical Director
Principal Investigator
Alnylam Pharmaceuticals
Eligibility Criteria
This trial is for adults aged 50 or older with probable Cerebral Amyloid Angiopathy (CAA) as per Boston Criteria, or those 30 and above with a known E693Q amyloid precursor protein gene mutation linked to Dutch-type CAA. It's not suitable for individuals who don't meet these specific conditions.Inclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive multiple doses of ALN-APP or placebo during the double-blind treatment period
Follow-up
Participants are monitored for safety and effectiveness after treatment
Open-label extension (optional)
Participants may opt into continuation of treatment with ALN-APP long-term
Treatment Details
Interventions
- ALN-APP (RNA-based Therapy)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Alnylam Pharmaceuticals
Lead Sponsor
Dr. Yvonne Greenstreet
Alnylam Pharmaceuticals
Chief Executive Officer since 2021
MD from the University of Leeds, MBA from INSEAD
Dr. Pushkal Garg
Alnylam Pharmaceuticals
Chief Medical Officer since 2016
MD from Columbia University